Dual roles for coactivator activator and its counterbalancing isoform coactivator modulator in human kidney cell tumorigenesis

Cancer Research

Volumn 68, Issue 19, 2008, Pages 7887-7896

  Yun, Kyoung Kang ^a   Schiff, Rachel ^a   Ko, Lan ^b   Wang, Tao ^a   Tsai, Sophia Y ^a   Tsai, Ming Jer ^a   O'Malley, Bert W ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CCND1 PROTEIN; COACTIVATOR ACTIVATOR PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 1B; HISTONE DEACETYLASE 3; HISTONE H3; MESSENGER RNA; MYC PROTEIN; PROTEIN; RNA POLYMERASE II; S PHASE KINASE ASSOCIATED PROTEIN 2; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ACETYLATION; ANCHORAGE INDEPENDENT GROWTH; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DOWN REGULATION; EMBRYO; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY CARCINOMA; MOUSE; NONHUMAN; ONCOGENE C MYC; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; TUMOR XENOGRAFT;

ANIMALS; CARCINOMA, RENAL CELL; CELL CYCLE; CELL LINE; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CYCLIN D1; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, MYC; GENES, TUMOR SUPPRESSOR; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; KIDNEY; KIDNEY NEOPLASMS; MICE; MICE, NUDE; MODELS, BIOLOGICAL; PROTEIN ISOFORMS; S-PHASE KINASE-ASSOCIATED PROTEINS; TRANSPLANTATION, HETEROLOGOUS;

EID: 54249091205     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-1734     Document Type: Article

References (32)

1. Modrek B, Lee C. A genomic view of alternative splicing. Nat Genet 2002;30:13-9.
2. Maniatis T, Tasic B. Alternative pre-mRNA splicing and proteome expansion in metazoans. Nature 2002;418:236-43.
3. Srebrow A, Kornblihtt AR. The connection between splicing and cancer. J Cell Sci 2006;119:2635-41.
4. Faustino NA, Cooper TA. Pre-mRNA splicing and human disease. Genes Dev 2003;17:419-37.
5. Julian P. Venables. Unbalanced alternative splicing and its significance in cancer. Bioessays 2006;28:378-86.
6. Brinkman BMN. Splice variants as cancer biomarkers. Clin Biochem Spec Issue: Recent Adv Cancer Biomarkers 2004;37:584-94.
7. Brett D, Whitehouse S, Antonson P, Shipley J, Cooper C, Goodwin G. The SYT protein involved in the t(X;18) synovial sarcoma translocation is a transcriptional activator localised in nuclear bodies. Hum Mol Genet 1997;6:1559-64.
8. Iwasaki T, Chin WW, Ko L. Identification and characterization of RRM-containing coactivator activator (CoAA) as TRBP-interacting protein, and its splice variant as a coactivator modulator (CoAM). J Biol Chem 2001;276:33375-83.
9. Auboeuf D, Dowhan DH, Li X, et al. CoAA, a nuclear receptor coactivator protein at the interface of transcriptional coactivation and RNA splicing. Mol Cell Biol 2004;24:442-53.
10. Lonard DM, Lanz RB, O'Malley BW. Nuclear receptor coregulators and human disease. Endocr Rev 2007;28:575-87.
11. Perani M, Antonson P, Hamoudi R, et al. The protooncoprotein SYT interacts with SYT-interacting protein/co-activator activator (SIP/CoAA), a human nuclear receptor co-activator with similarity to EWS and TLS/FUS family of proteins. J Biol Chem 2005;280:42863-76.
12. Lee SK, Anzick SL, Choi JE, et al. A nuclear factor, ASC-2, as a cancer-amplified transcriptional coactivator essential for ligand-dependent transactivation by nuclear receptors in vivo. J Biol Chem 1999;274:34283-93.
13. Graham FL, Smiley J, Russell WC, Nairn R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol 1977;36:59-74.
14. Cheng JD, Dunbrack RL, Jr., Valianou M, Rogatko A, Alpaugh RK, Weiner LM. Promotion of tumor growth by murine fibroblast activation protein, a serine protease, in an animal model. Cancer Res 2002;62:4767-72.
15. Ho DH, Vu H, Brown SAN, Donohue PJ, Hanscom HN, Winkles JA. Soluble tumor necrosis factor-like weak inducer of apoptosis overexpression in HEK293 cells promotes tumor growth and angiogenesis in athymic nude mice. Cancer Res 2004;64:8968-72.
16. Carrano AC, Eytan E, Hershko A, Pagano M. SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nat Cell Biol 1999;1:193-9.
17. Rhodes DR, Yu J, Shanker K, et al. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 2004;6:1-6.
18. Higgins JPT, Shinghal R, Gill H, et al. Gene expression patterns in renal cell carcinoma assessed by complementary DNA microarray. Am J Pathol 2003;162:925-32.
19. Sankar N, Baluchamy S, Kadeppagari RK, Singhal G, Weitzman S, Thimmapaya B. p300 provides a corepressor function by cooperating with YY1 and HDAC3 to repress c-Myc. Oncogene. Epub 2008 Jun 9.
20. Gordan JD, Bertout JA, Hu CJ, Diehl JA, Simon MC. HIF-2α promotes hypoxic cell proliferation by enhancing c-myc transcriptional activity. Cancer Cell 2007;11:335-47.
21. Yao M, Shuin T, Misaki H, Kubota Y. Enhanced expression of c-myc and epidermal growth factor receptor (C-erbB-1) genes in primary human renal cancer. Cancer Res 1988;48:6753-7.
22. Trudel M, D'Agati V, Costantini F. C-myc as an inducer of polycystic kidney disease in transgenic mice. Kidney Int 1991;39:665-71.
23. Zhang H, Gao P, Fukuda R, et al. HIF-1 inhibits mitochondrial biogenesis and cellular respiration in VHL-deficient renal cell carcinoma by repression of C-MYC activity. Cancer Cell 2007;11:407-20.
24. Wolf G, Schanze A, Stahl RA, Shankland SJ, Amann K. p27(Kip1) Knockout mice are protected from diabetic nephropathy: evidence for p27(Kip1) haplotype insufficiency. Kidney Int 2005;68:1583-9.
25. Pertia A, Nikoleishvili D, Trsintsadze O, Gogokhia N, Managadze L, Chkhotua A. Loss of p27(Kip1) CDKI is a predictor of poor recurrence-free and cancer-specific survival in patients with renal cancer. Int Urol Nephrol 2007;39:381-7.
26. Sui Y, Yang Z, Xiong S, et al. Gene amplification and associated loss of 5′ regulatory sequences of CoAA in human cancers. Oncogene 2007;26:822-35.
27. Coste A, Antal MC, Chan S, et al. Absence of the steroid receptor coactivator-3 induces B-cell lymphoma. EMBO J 2006;25:2453-64.
28. Frisch SM, Mymryk JS. Adenovirus-5 E1A: paradox and paradigm. Nat Rev Mol Cell Biol 2002;3:441-52.
29. Perkins ND. NF-κB: tumor promoter or suppressor? Trends Cell Biol 2004;14:64-9.
30. Majumder S. REST in good times and bad: roles in tumor suppressor and oncogenic activities. Cell Cycle 2006;5:1929-35.
31. Xu J, Liao L, Ning G, Yoshida-Komiya H, Deng C, O'Malley BW. The steroid receptor coactivator SRC-3 (p/CIP/RAC3/AIB1/ACTR/TRAM-1) is required for normal growth, puberty, female reproductive function, and mammary gland development. Proc Natl Acad Sci U S A 2000;97:6379-84.
32. Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999;17:1474-81.